REG - e-Therapeutics plc - Notice of AGM and Posting of Annual Report

E-TherapeuticsAnnouncement

17/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220517:nRSQ6255La&default-theme=true

RNS Number : 6255L  e-Therapeutics plc  17 May 2022

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Notice of Annual General Meeting and Posting of Annual Report and Accounts

 

 

London, UK, 17 May 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
specialist in computational drug discovery with a focus on developing RNA
interference ("RNAi") therapeutics, announces that its Annual Report and
Accounts for the year ended 31 January 2022, which includes the notice of its
2022 Annual General Meeting ("AGM") have been posted to shareholders today and
are available on the Company's website at:

https://www.etherapeutics.co.uk/application/files/1216/5167/3296/ETX_AR_2022.pdf
(https://www.etherapeutics.co.uk/application/files/1216/5167/3296/ETX_AR_2022.pdf)

 

The AGM will be held at 12:30p.m. on 19 July 2022 at 4 Kingdom Street,
Paddington, London, W2 6BD.

 

The right to attend and vote at the  AGM is determined by reference to the
Company's register of members.  Only a member entered in the register of
members as at close of business on 15 July 2022 (or, if the AGM is adjourned,
in the register of members as at the close of business on the date which is
two business days before the time of the adjourned  AGM) is entitled to
attend and vote at the  AGM.

 

Shareholders who wish to register their votes on the resolutions to be put to
the AGM should do so by completing and signing the proxy form that accompanies
the notice of the AGM (or appoint a proxy electronically if their shares are
held in CREST) in accordance with the instructions printed on the proxy form.

 

Please complete and return the form of proxy in accordance with the
instructions printed thereon as soon as possible and, in any event, so that it
is received by the Company's registrar, Neville Registrars Limited, Neville
House, Steelpark Road, Halesowen, B62 8HD not later than 12:30p.m. on 15 July
2022.

 

If you do not have a proxy form and believe that you should have one, or if
you have any additional queries on voting, please contact Neville Registrars
Limited.

 

 

 

Enquiries:

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Strategic Communications

      SP Angel Corporate Finance LLP

                                                                                       Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 
About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and
biology to accelerate the discovery of life-transforming medicines. The
Company has developed and validated a powerful, disease and modality agnostic
computational approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human disease
complexity.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e- therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAAFMMTMTMBBTT